您搜索了: difosfonatov (斯洛文尼亚语 - 英语)

85 % bolnic prej še ni prejemalo difosfonatov.
85% of patients were bisphosphonate-naïve.

zoledronska kislina pripada skupini difosfonatov in deluje primarno na kost.
zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone.

zoledronska kislina spada v skupino difosfonatov in deluje predvsem na kost.
zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone.

ibandronska kislina pripada skupini difosfonatov, ki specifično delujejo na kosti.
ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone.

ibandronska kislina spada v skupino difosfonatov, ki specifično delujejo na kosti.
ibandronic acid belongs to the bisphosphonate group of compounds which act specifically on bone.

pri sočasnem ali zaporednem dajanju zdravila avastin in intravenskih difosfonatov je potrebna previdnost.
caution should be exercised when avastin and intravenous bisphosphonates are administered simultaneously or sequentially.

selektivno delovanje difosfonatov na kostno tkivo temelji na njihovi veliki afiniteti do mineralizirane kosti.
their selective action on bone tissue is based on the high affinity of bisphosphonates for bone mineral.

osteonekroza čeljustnic†**, osteonekroza zunanjega sluhovoda (neželeni učinek skupine difosfonatov)
osteonecrosis of jaw†** osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction)†

zometo smejo uporabljati samo zdravniki kliniki, ki imajo izkušnje z uporabo difosfonatov za intravensko uporabo.
zometa must only be used by clinicians experienced in the administration of intravenous bisphosphonates.

preobčutljivost na zdravilno učinkovino, katerega od difosfonatov ali katero koli pomožno snov navedeno v poglavju 6.1.
hypersensitivity to the active substance, to any bisphosphonates or to any of the excipients listed in section 6.1.

te predhodno dobivali zdravilo iz skupine difosfonatov (uporabljajo se za zdravljenje ali preprečevanje kostnih bolezni),
you have previously been treated with a bisphosphonate (used to treat or prevent bone disorders)

pri sočasnem jemanju difosfonatov z aminoglikozidi je potrebna previdnost, ker lahko obe učinkovini znižata koncentracijo kalcija v serumu za daljše obdobje.
caution is advised when bisphosphonates are administered with aminoglycosides, since both substances can lower serum calcium levels for prolonged periods.

selektivno delovanje difosfonatov na kost temelji na njihovi veliki afiniteti do mineralizirane kosti, vendar natančen molekulski mehanizem zavrtja aktivnosti osteoklastov še ni jasen.
the selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear.

od četrtega do osmega leta zdravljenja so bolnicam dovolili sočasno jemanje difosfonatov, kalcitonina in fluoridov in vse bolnice iz te raziskave so jemale dodatke kalcija in vitamina d.
from the 4th to the 8th year, patients were permitted the concomitant use of bisphosphonates, calcitonin and fluorides and all patients in this study received calcium and vitamin d supplementation.

bolniki, ki prejemajo zdravilo zoledronska kislina teva ne smejo sočasno prejemati teh zdravil ali katerega koli od drugih difosfonatov, saj učinki kombinacije navedenih učinkovin niso znani.
patients being treated with zoledronic acid teva should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.

selektivno delovanje difosfonatov na kost temelji na njihovi veliki afiniteti do mineralizirane kosti, vendar je natančen molekularni mehanizem, ki privede do inhibicije osteoklastne aktivnosti, še nejasen.
the selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear.

analiza preživetja po podskupinah je pokazala dosledno korist zdravljenja z zdravilom xofigo za preživetje, ne glede na celokupno vrednost alkalne fosfataze, sočasno uporabo difosfonatov na začetku zdravljenja in predhodno uporabo docetaksela.
subgroup survival analysis showed a consistent survival benefit for treatment with xofigo, independent of total alkaline phosphatase (alp), use of bisphosphonates at baseline and prior use of docetaxel.

potentnost difosfonatov (večje tveganje pri visoko potentnih učinkovinah), pot uporabe (večje tveganje pri parenteralni uporabi) in kumulativni odmerek
potency of the bisphosphonate (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bisphosphonate.

sočasno zdravljenje osteoporoze je vključevalo: kalcitonin, raloksifen, tamoksifen, hormonsko nadomestno zdravljenje, tibolon; uporaba drugih difosfonatov pri tem ni bila dovoljena.
concomitant osteoporosis therapy included: calcitonin, raloxifene, tamoxifen, hormone replacement therapy, tibolone; but excluded other bisphosphonates.

zmanjšanje tveganja je bilo 51- odstotno v skupini bolnikov, ki še niso jemali difosfonatov, in 42-odstotno pri bolnikih, ki so lahko sočasno jemali druga zdravila za zdravljenje osteoporoze.
the risk reduction was 51% in bisphosphonate-naïve patients and 42% in patients allowed to take concomitant osteoporosis therapy.